




Supplementary Fig. 1. (A) Risk of bias graph: review of authors' judgements about risk of bias item presented as percentages across all included studies. (B) Risk of bias summary: review of authors' judgements about risk of bias for each item for each included study.



Supplementary Fig. 2. Funnel plot assessing the publication bias for key outcomes of this meta-analysis. (A) Treatment emergent adverse events with SGLT2i in type 2 diabetes mellitus (T2DM) as compared to placebo; (B) serious adverse events with SGLT2i in T2DM as compared to placebo; (C) DKA with SGLT2i in T2DM as compared to placebo; (D) UTI with SGLT2i in T2DM as compared to placebo; (E) severe hypoglycemia requiring assistance with SGLT2i in T2DM as compared to placebo. SGLT2i, sodium-glucose cotransporter-2 inhibitors; DKA, diabetic ketoacidosis; SE, standard error; OR, odds ratio.